Moffitt Cancer Center has initiated a major effort to increase the number of investigator-initiated early phase clinical studies. For FY2005, investigators at Moffitt Cancer Center enrolled 490 patients on pilot, phase I or I studies. The Clinical Investigations Program has significantly expanded the phase I effort since the previous submission in 2000. The percentage of subjects enrolled onto Investigator-initiated trials has almost doubled (23% to 44%) over the course of the previous grant period. The proportion of accruals to phase I or I/I I studies remains above 40% of all accruals. The support of innovative phase I and feasibility studies is a clear institutional priority for the coming years of the grant cycle. The scope of this important activity will include outpatient based studies as well as studies conducted for inpatients. Phase I and feasibility studies will take place in both arenas, staffed by research nurses who will supplement the data management core. The maturation of interactions between basic scientists and clinicians, the interprogrammatic working groups, and the establishment of the clinical research unit and translational laboratory support the need for increased numbers of experienced research nursing staff. The institution continues to support the growth of the Phase I Program as demonstrated by the expansion of the Clinical Research Unit in 2001. The current outpatient CRU outpatient area consists of seven treatment rooms (seven beds), 3 infusion area (9 infusion chairs) and three offices, which house five research nurses, two study coordinators, two physician assistants and the Manager of the CRU. Further expansion of this area will be complete in 2007 and will provide additional treatment areas that will expand capacity by at least 60%.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-11
Application #
7780388
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-02-01
Budget End
2010-01-31
Support Year
11
Fiscal Year
2009
Total Cost
$153,707
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Gonzalez, Brian D; Hoogland, Aasha I; Kasting, Monica L et al. (2018) Psychosocial impact of BRCA testing in young Black breast cancer survivors. Psychooncology 27:2778-2785
Akuffo, Afua A; Alontaga, Aileen Y; Metcalf, Rainer et al. (2018) Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon. J Biol Chem 293:6187-6200
Mahajan, Nupam P; Coppola, Domenico; Kim, Jongphil et al. (2018) Blockade of ACK1/TNK2 To Squelch the Survival of Prostate Cancer Stem-like Cells. Sci Rep 8:1954
Rounbehler, Robert J; Berglund, Anders E; Gerke, Travis et al. (2018) Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiol Biomarkers Prev 27:1376-1383
Christy, Shannon M; Schmidt, Alyssa; Wang, Hsiao-Lan et al. (2018) Understanding Cancer Worry Among Patients in a Community Clinic-Based Colorectal Cancer Screening Intervention Study. Nurs Res 67:275-285
Chang, James M; Kosiorek, Heidi E; Dueck, Amylou C et al. (2018) Stratifying SLN incidence in intermediate thickness melanoma patients. Am J Surg 215:699-706
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221
Sun, X; Ren, Y; Gunawan, S et al. (2018) Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099. Leukemia 32:1246-1249
Porubsky, Caitlin; Teer, Jamie K; Zhang, Yonghong et al. (2018) Genomic analysis of a case of agminated Spitz nevi and congenital-pattern nevi arising in extensive nevus spilus. J Cutan Pathol 45:180-183
Zhu, Genyuan; Nemoto, Satoshi; Mailloux, Adam W et al. (2018) Induction of Tertiary Lymphoid Structures With Antitumor Function by a Lymph Node-Derived Stromal Cell Line. Front Immunol 9:1609

Showing the most recent 10 out of 1254 publications